Pfizer, BioNTech unveil data that gave partners their lead vaccine

Pfizer and BioNTech have revealed the clinical data that led the partners to choose which vaccine they would send into Phase III testing for COVID-19.

Side-by-side Phase I/II safety and immunogenicity data for the 30 µg doses of BNT162b2, the Phase III candidate and dose selected by Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), and BNT161b1, the partners’ original lead vaccine, in volunteers aged 18-55 and 65-85 showed the former to be safer and more immunogenic. The data, which also include results for lower doses, were published Thursday in medRxiv...